Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

Author(s):: Lam, S.W.; Nota, N.M.; Groot, S.M. de; Jager, A.; Bos, M.M.; Linn, S.C.; Bosch, J. van den; Braun, H.J.; Velden, A.M.T. van der; ; Portielje, J.E.A.; Kroep, J.R.; Honkoop, A.H.; Smorenburg, C.H.; Tanis, B.; Riel, J.M.G.H. van; Terwogt, J.M.M.; Boer, M.O. den; Douma, J.; Jeurissen, F.; Berends, J.; Tinteren, H. van;